CRISPR/dCas-mediated counter-silencing: Reprogramming dCas proteins into antagonists of xenogeneic silencers

Johanna Wiechert,Biel Badia Roige,Doris Dohmen-Olma,Hindra Hindra,Xiafei Zhang,Marie Elliot,Julia Frunzke

DOI: https://doi.org/10.1101/2024.08.29.610263

2024-08-30

Abstract:Lsr2-like nucleoid-associated proteins function as xenogeneic silencers (XSs) inhibiting expression of horizontally acquired, AT-rich DNA in actinobacteria. Interference with transcription factors can lead to counter-silencing of XS target promoters but typically requires promoter engineering. In this study, we developed a novel CRISPR/dCas-mediated counter-silencing (CRISPRcosi) approach by using nuclease-deficient dCas enzymes to counteract the Lsr2-like XS protein CgpS in Corynebacterium glutamicum or Lsr2 in Streptomyces venezuelae. Systematic in vivo reporter studies with dCas9 and dCas12a and various guide RNAs revealed effective counter-silencing of different CgpS target promoters in response to guide RNA/dCas DNA binding, independent of promoter sequence modifications. The most prominent CRISPRcosi effect was observed when targeting the CgpS nucleation site, an effect that was also seen in S. venezuelae when targeting a known Lsr2 nucleation site. Analyzing the system in strains lacking the XS protein CgpS revealed varying strengths of counteracting CRISPR interference effects based on the target position and strand. Genome-wide transcriptome profiling in sgRNA/dCas9 co-expressing wild-type strains revealed high counter-silencing specificity with minimal off-target effects. Thus, CRISPRcosi provides a promising system for the precise upregulation of XS target genes with significant potential for studying gene networks as well as for developing applications in biotechnology and synthetic biology.

Microbiology

What problem does this paper attempt to address?

The problem this paper attempts to address is: how to reactivate gene expression suppressed by xenogeneic silencers (XS) without modifying the silent gene sequences.

Specifically, the authors developed a CRISPR/dCas-based anti-silencing technology (CRISPRcosi), which uses a nuclease-deactivated dCas protein bound to specific guide RNA (sgRNA) to interfere with the action of xenogeneic silencers (such as CgpS and Lsr2), thereby achieving precise reactivation of target genes. This method aims to overcome the limitations of traditional anti-silencing methods that rely on the insertion of specific transcription factor binding sites, providing a more flexible and broadly applicable gene regulation tool for studying gene networks and applications in biotechnology and synthetic biology.